Correlative study on retinal microvascular changes and sex hormones in male patients with central serous chorioretinopathy

Central serous chorioretinopathy (CSC) is a disease in which the outer retinal barrier is damaged with high incidence in young adult males. We aimed to analyze the correlations between retinal microvascular changes and sex hormone levels. The vascular density of the superficial retinal capillary plexus (SCP), deep retinal capillary plexus (DCP), foveal avascular zone (FAZ) area, choriocapillary blood flow area, and the subfoveal choroidal thickness (SCT) were investigated by optical coherence tomography angiography (OCTA). We also determined the levels of sex hormones (adrenaline (AD), norepinephrine (NE), dopamine (DA), corticosteroids (Cor), aldosterone (ALD), estradiol (E2) and total testosterone (TT)). The relationship between sex hormone levels and OCTA parameters was then determined. We detected significantly higher levels of NE, Cor and TT in serum from the observation group than in the control group (p < 0.05). Significant correlations were identified between SCT and choriocapillary blood flow area in the affected eyes, contralateral eyes and healthy eyes in the control group (p < 0.05). SCT levels of both eyes in the observation group were higher and the choriocapillary blood flow area was smaller than in the control group. The SCT in affected eyes from the observation group were higher than the contralateral eyes (p < 0.05). The choriocapillary blood flow area was significantly smaller than in the contralateral eyes (p < 0.05). Correlation analysis unveiled that NE, Cor and TT levels were positively correlated with SCT in CSC patients and negatively correlated with choriocapillary blood flow area (p < 0.05). The serum levels of sex hormone levels in male CSC patients were different from those in healthy men of the same age. Our findings suggest that the serum levels of NE, Cor and TT levels may influence the pathogenesis of CSC by affecting SCT thickness and choriocapillary blood flow.

Male; Central serous chorioretinopathy; Optical coherence tomography angiography; Sex hormones; Retinal microvascular changes

[1] Rugo HS. Continuing advancements in breast cancer care unraveling the data from the 2020 San Antonio breast cancer symposium. Oncology. 2021; 35: 11–13.

[2] Siwiec-Prościńska J, Prościnski T, Kociecki J, Pecold K. Central serous choroidoretinopathy—the characteristics of the clinical picture and the evaluation of the influence of general conditions at the prognosis and the course of the disease. Metaanalysis. Klin Oczna. 2009; 111: 258–262. (In Polish)

[3] Yu S, Park J, Kim K, Kang M, Kim E. Central serous chorioretinopathy: treatment. Taiwan Journal of Ophthalmology. 2022; 12: 394.

[4] Entezari M, Ramezani A, Yaseri M. Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy. Korean Journal of Ophthalmology. 2012; 26: 139.

[5] Wali UK, Al-Kharousi N, Hamood H. Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization—first report from the sultanate of oman. Oman Medical Journal. 2008; 23: 282–286.

[6] Kanda P, Gupta A, Gottlieb C, Karanjia R, Coupland SG, Bal MS. Pathophysiology of central serous chorioretinopathy: a literature review with quality assessment. Eye. 2022; 36: 941–962.

[7] Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Progress in Retinal and Eye Research. 2022; 86: 100973.

[8] Lu B, Chao G, Xie L. Optical coherence tomography angiography in retinitis pigmentosa: a narrative review. Medicine. 2022; 101: e30068.

[9] Borrelli E, Battista M, Sacconi R, Querques G, Bandello F. Optical coherence tomography angiography in diabetes. Asia-Pacific Journal of Ophthalmology. 2021; 10: 20–25.

[10] Müller P, Pfau M, Schmitz-Valckenberg S, Fleckenstein M, Holz F. Optical coherence tomography-angiography in geographic atrophy. Ophthalmologica. 2021; 244: 42–50.

[11] Association WM. World medical association declaration of Helsinki. Ethical principles for medical research involving human subjects. Bulletin of the World Health Organization. 2001; 79: 373.

[12] Jain M, Mohan S, van Dijk EC. Central serous chorioretinopathy: pathophysiology, systemic associations, and a novel etiological classification. Taiwan Journal of Ophthalmology. 2022; 12: 381.

[13] Kaye R, Chandra S, Sheth J, Boon CJF, Sivaprasad S, Lotery A. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities. Progress in Retinal and Eye Research. 2020; 79: 100865.

[14] Battaglia Parodi M, Arrigo A, Iacono P, Falcomatà B, Bandello F. Central serous chorioretinopathy: treatment with laser. Pharmaceuticals. 2020; 13: 359.

[15] Lei C, Hua R, Duan J, Zhang M. Retinal pigment epithelium aperture in acute central serous chorioretinopathy: another novel possible pathological mechanism. European Journal of Ophthalmology. 2022; 32: NP103–NP108.

[16] Chronopoulos A, Kakkassery V, Strobel MA, Fornoff L, Hattenbach L. The significance of pigment epithelial detachment in central serous chorioretinopathy. European Journal of Ophthalmology. 2021; 31: 556–565.

[17] Jeon SH, Kim M, Lee J, Roh Y. The effect of selective retina therapy for bevacizumab-resistant chronic central serous chorioretinopathy. Ophthalmologica. 2022; 245: 91–100.

[18] Goel N, Mehta A, Gupta A. Multifocal electroretinography-assisted anatomical and functional evaluation of subthreshold green laser in acute central serous chorioretinopathy. Indian Journal of Ophthalmology. 2021; 69: 2341.

[19] Pichi F, Hay S. Use of optical coherence tomography angiography in the uveitis clinic. Graefe’S Archive for Clinical and Experimental Ophthalmology. 2023; 261: 23–36.

[20] Coffey AM, Hutton EK, Combe L, Bhindi P, Gertig D, Constable PA. Optical coherence tomography angiography in primary eye care. Clinical and Experimental Optometry. 2021; 104: 3–13.

[21] Brinks J, van Dijk EHC, Tsonaka R, Meijer OC, Boon CJF. Sex hormones in males and females with active central serous chorioretinopathy. Ophthalmologica. 2022; 245: 555–562.

[22] Singh SR, Iovino C, Zur D, Masarwa D, Iglicki M, Gujar R, et al. Central serous chorioretinopathy imaging biomarkers. British Journal of Ophthalmology. 2022; 106: 553–558.

[23] Zeng Q, Yao Y, Li S, Yang Z, Qu J, Zhao M. Comparison of swept-source OCTA and indocyanine green angiography in central serous chorioretinopathy. BMC Ophthalmol. 2022; 22: 380.

[24] Schellevis RL, Altay L, Kalisingh A, Mulders TWF, Sitnilska V, Hoyng CB, et al. Elevated steroid hormone levels in active chronic central serous chorioretinopathy. Investigative Ophthalmology & Visual Science. 2019; 60: 3407.

[25] Ulaş F, Uyar E, Tekçe H, Çelebi S. Can hypothyroidism cause acute central serous chorioretinopathy? Seminars in Ophthalmology. 2019; 34: 533–540.

[26] Zhao C, Huang Y, Chen L, Ye S, Liu XQ. The association between circulating sex hormones and central serous chorioretinopathy: a case-control study. Therapeutics and Clinical Risk Management. 2022; 18: 855–865.

[27] Chang YS, Weng SF, Wang JJ, Jan RL. Temporal association between topical ophthalmic corticosteroid and the risk of central serous chori-oretinopathy. International Journal of Environmental Research and Public Health. 2020; 17: 9455.

[28] Çiloğlu E, Unal F, Dogan NC. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. Graefe’S Archive for Clinical and Experimental Ophthalmology. 2018; 256: 1111–1116.

[29] Nudleman E, Witmer MT, Kiss S, Williams GA, Wolfe JD. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina. 2014; 34: 2128–2132.